Close

Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors

Go back to Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors